{
  "docId": "019de071-fee7-744f-89ad-50de02e7ef2c",
  "docSlug": "b5a336d0fe4b7b554c90c4664e01c224",
  "documentTitle": "Comera | SPAC Presentation Deck | 33 slides",
  "authorId": "comera",
  "authorName": "Comera Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 33,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-fee7-744f-89ad-50de02e7ef2c/6",
  "deckHref": "/decks/019de071-fee7-744f-89ad-50de02e7ef2c",
  "deckJsonHref": "/decks/019de071-fee7-744f-89ad-50de02e7ef2c.json",
  "deckAnchorHref": "/decks/019de071-fee7-744f-89ad-50de02e7ef2c#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "list",
      "text": "Compelling Valuation and Attractive Entry Point: Proprietary platform enables potential for significant value creation; As Comera continues to execute on its business plan, it should trade in line with more developed biologics companies that tend to trade at higher valuations",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ed5f89f-6e5e-409e-8919-77c8f4cc3cf0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "list",
      "text": "Multiple Pharmaceutical Partnerships: Agreements with top-tier pharma collaborators for high-value, late-stage/marketed, licensed products with significant licensing, milestone payment and royalty potential; Additional partnerships expected",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31b180f2-c4df-4e34-a91d-61035fbf4c7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.75
      },
      "kind": "list",
      "text": "Expertise and Intellectual Property: Team with successful track record of drug development and life sciences operating experience; Extensive IP protection",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "445dfef6-e3da-4621-857b-7924874be19b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.6
      },
      "kind": "list",
      "text": "Proprietary Product Pipeline: Proprietary pipeline of biologics in development targeting substantial markets and high unmet needs; First IND filing expected in Q1 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a382d80-1809-416d-8531-fd5339dd2245",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "list",
      "text": "Proprietary Excipient Technology Platform: Proprietary SQore excipient platform technology to develop subcutaneous biologics for improved patient outcomes; Lead caffeine-based patented excipient validated in peer-reviewed study and initial in vivo safety studies provide evidence of tolerability",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5927752-63ee-42d6-b36c-0eb8509a1fb1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.3
      },
      "kind": "list",
      "text": "Significant Opportunity: Most biologics delivered intravenously despite significant limitations for patients and healthcare system; $220B addressable market in 2020 and expected to grow to $422B in 2025",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f964338d-9788-4259-a292-9dda5c71cbaf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Comera Life Sciences Investment Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0cb721f-cd97-44a1-b208-a6767ba84380",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "53eff83b-cb34-4dba-8712-4c589093fc14",
      "evidence": "Comera Life Sciences Investment Highlights",
      "confidence": 0.9
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "4f58f7d7-809b-4c74-82f9-2add07f270ba",
      "evidence": "list/bullet: Proprietary Excipient Technology Platform: Proprietary SQore excipient platform technology to develop subcutaneous biologics for improved patient outcomes;",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}